Source : People’s Democracy, 3 May, 2015
A GROUP of individuals and organisations has expressed concerns over the central government’s move to review India’s positions on the issue of Intellectual Property Rights (IPR), ahead of Prime Minister Narendra Modi’s visit to the United States. Referring to commerce and industry minister Nirmala Sitharaman’s recent remarks on the matter, the group, in a statement on September 23, said “we are concerned about the timing that has been chosen to undertake a ministry-level exercise on India’s IPR policy and apprehend that the proposed exercise could become a hostage to the pressures of the US government and companies”.
Sitharaman, in a press briefing on 8 September, had indicated that the government would roll out a revised policy on IPR. She had also indicated that this policy would focus on boosting innovation and tone up the overall administration, besides setting up a think-tank to strengthen the country’s patent regime. She had said “India does not have an IPR policy. This is the first time we are coming out with an IPR policy. We are very strong in IPR and we certainly want to protect our interest. IPR policy issues have been hanging for quite a long time and the new policy will give direction in terms of protecting IPR of India. With the US, we have (certain) issues. India has become a brand in terms of pharma. Because India does not have any policy, developed nations are picking holes in India’s IPR laws”.
The statement made by the minister that India does not have an IPR policy is not true. The current Indian IP legal regime represents the policy framework on IPR, which was adopted after considerable debate inside and outside Parliament. The strength of this IPR policy is reflected well in successful establishment of the Indian pharmaceutical industry within three decades. Until 1995, its success was enabled by the Indian Patents Act, 1970, which limited patent protection to process innovations. After 1995, the success was ensured by Parliament’s decision to take full benefit of the transition period of 10 years available under the WTO Agreement on Trade-Related Aspects of Intellectual Property (TRIPS). India delayed the implementation of product patent and chose to limit the scope of patent protection through introduction of Section 3 (d) of the Indian Patents Act. India also added article 3 (j) on biological processes not being inventions to protect its biotechnological innovations in the sector of agriculture and health. Section 3 (d) rejects patents that do not involve real innovation, an issue that foreign pharmaceutical companies are not in agreement with. Similarly, compulsory licensing provisions in the Indian Patents Act aim to ensure that patent holders do not abuse patents to develop monopolies and thereby charge exorbitant prices which would result in denial of access to medicine at affordable prices to the people of India.
India’s IPR policy is TRIPS-compliant. India chose to use the health safeguards available in the TRIPS agreement, to protect the interests of Indian patients as well as millions of people living in other developing countries. The law requires that patented inventions are available to the public at affordable prices as well as obligates the patent holders to work their patents in India. By making use of flexibilities in the TRIPS agreement, the Indian Patents Act and Policy reduce options to pharmaceutical companies, be they Indian or foreign, to profit from diseases or those suffering from them. The Indian law has stood the test of time and judicial scrutiny. It is also increasingly serving as model legislation for many developing countries including Brazil.
The group also expressed concern about the implications of the minister’s statement, linking innovation with strengthened IP protection. Globally, there is no conclusive proof that strengthened IP protection promotes innovation and we should be under no illusion that strong IP protection can boost innovative activities in India. Instead of seeking to strengthen IP protection, the government needs to enhance public investment in drug discovery and development research, to promote innovations that can lead to new drug discovery in India.
We are worried about the implications of the statement by the minister that the country’s IPR policy will “not be restrictive or regressive” but will “only give clarity and consistency without any overlap or contradictions”. We believe that the problem is not with the lack of clarity and consistency in the existing IPR policy but rather with the lack of its implementation by the political leadership.
We are also of the view that the continued efforts by trans-national corporations on linking strong IPR as a precondition to attracting foreign direct investment (FDI) are misplaced. There is no evidence to link IPR with inflow of FDI. We urge the government not to fall prey to such organised propaganda. While the US administration has been hostile towards India’s sovereign laws because they run contrary to the interests of US-based pharmaceutical companies, it has not prevented US-based pharmaceutical companies from operating in India. They are also able to patent products that are patentable under the Indian Act.
Meanwhile, the US continues to target India’s patent system and has amplified its pressure on India. For example, the Global Intellectual Property Centre of the US Chamber of Commerce accused India of harbouring the “weakest” IP environment among countries that it studied. Further, the US International Trade Commission (ITC) has initiated an investigation on India’s industrial policy, which is primarily focused on India’s intellectual property regime and its impact on the US economy. Similarly, the United States Trade Representative (USTR) continues to make illegitimate threats (inconsistent with the principles of the multilateral decision making and dispute settlement processes of the WTO) of unilateral trade sanctions against India through the Special 301 process. It is to undertake an out-of-cycle review of India’s intellectual property protection and enforcement standards in the coming months.
The group believes that during the forthcoming visit of the Prime Minister to the US, there will be tremendous pressure on India to modify its Patents Act in the following ways: Dilution of patentability criteria, including those enshrined in Section 3(d) of the Indian Patents Act; Limitations to the use of compulsory licensing for access to patented medicines through generic production; Prohibition of the use of pre- and post-grant oppositions that are currently being used to challenge fraudulent patent claims by foreign MNCs; Strengthening of IP enforcement, so that the Indian judicial system would police and secure the patent rights of foreign entities; and Introduction of ‘data exclusivity’, thus extending patent monopolies and delaying the entry of generics.
India needs an IP regime, especially a patent regime, which can facilitate technology catch-up and that aids industrialisation. An IP regime that favours trans-national companies would act contrary to the Prime Minister’s efforts to revive the manufacturing sector in India. We underline our demand that the Centre should not carry out any amendment to the Indian Patents Act to increase patent protection. We strongly urge the government to proactively use the flexibilities in the Patents Act such as government use and compulsory license. In fact, smaller developing countries, with much less bargaining power, have issued more compulsory licenses than just the one that India has granted.
We call upon the Prime Minister, during his visit to the US, not to make any legal or political commitment that compromises flexibilities in the Indian Patents Act for facilitating access to medicines and safeguarding public health, which is based on policies and principles approved by Indian Parliament and is fully consistent with international laws.
The signatories include former director of Central Drug Research Institute Dr. Nityanand, former secretary of Health and Family Planning Ministry S P Shukla, former foreign secretary Muchkund Dubey, JNU professors Biswajit Dhar and B S Chimni, and Dinesh Abrol on behalf of National Working Group on Patent Laws, Amit Sengupta of Jan Swasthya Abhiyan, Malini Aisola of Oxfam India, Ramya Sheshadri of Lawyers Collective, Vandana Shiva of Research Foundation for Science Technology & Ecology (RFSTE) and Amitava Guha of National Campaign Committee on Drug Policy, among others.